Status:
UNKNOWN
Pharmacokinetics and Pharmacodynamics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade
Lead Sponsor:
Guangzhou General Hospital of Guangzhou Military Command
Conditions:
Pharmacokinetics
Pharmacodynamics
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to illustrate pharmacokinetics and pharmacodynamics of sugammadex in reversal of vecuronium-induced neuromuscular blockade in anesthesia obese patients undergoing bariatri...
Detailed Description
16 obese patients undergoing bariatric surgery were divided into 2 groups according to body mass index (BMI), including obese group (O group, n=8, 25≤BMI≤39.9kg/m²) and morbidly obese group (M group, ...
Eligibility Criteria
Inclusion
- ASA: Ⅰ\~Ⅲ
- BMI≥25kg/m²
- Patients receiving bariatric surgery.
Exclusion
- Pregnant or lactating women
- Neuromuscular diseases
- Malignant hyperthermia or allergic history during general anesthesia
- Drugs that react with rocuronium and vecuronium were taken
Key Trial Info
Start Date :
July 16 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2020
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04131218
Start Date
July 16 2019
End Date
July 1 2020
Last Update
March 31 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangzhou Military Region General Hospital, Department of Anesthesiology
Guangzhou, Guangdong, China, 510010